From the Journals

Complete blood count scoring can predict COVID-19 severity 


 

A more objective assessment of risk

The study demonstrated that SARS-CoV-2 infection is characterized by hemocytometric changes over time. These changes, reflected together in the prognostic score, could aid in the early identification of patients whose clinical course is more likely to deteriorate over time.

The findings also support other work that shows men are more likely to present to the hospital with COVID-19, and that older age and presence of comorbidities add to overall risk. “However,” the researchers noted, “not all young patients had a mild course, and not all old patients with comorbidities were critical.”

Therefore, the prognostic score can help identify patients at risk for severe progression outside other risk factors and “support individualized treatment decisions with objective data,” they added.

Dr. Reichberg called the concept of combining CBC parameters into one score “very valuable.” However, he added that incorporating an index into clinical practice “has historically been tricky.”

The results “probably have to be replicated,” Dr. Reichberg said.

He added that it is likely a CBC-based score will be combined with other measures. “I would like to see an index that combines all the tests we do [for COVID-19], including complete blood count.”

Dr. Van der Ven shared the next step in his research. “The algorithm should be installed on the hematology analyzers so the prognostic score will be automatically generated if a full blood count is asked for in a COVID-19 patient,” he said. “So implementation of score is the main focus now.”

Dr. van der Ven disclosed an ad hoc consultancy agreement with Sysmex Europe. Sysmex Europe provided the reagents in the study free of charge; no other funders were involved. Dr. Reichberg has disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

COVID-19 anticoagulation trials ‘paused’ for futility, safety
MDedge Hematology and Oncology
Call to arms: vaccinating the health workforce of 21 million strong
MDedge Hematology and Oncology
Moderna’s COVID-19 vaccine deemed ‘highly effective,’ but further studies needed
MDedge Hematology and Oncology
COVID-19 mortality rates declined, but vary by hospital
MDedge Hematology and Oncology
New resilience center targets traumatized health care workers
MDedge Hematology and Oncology
Scant risk for SARS-CoV-2 from hospital air
MDedge Hematology and Oncology
Cancer treatment delays are deadly: 5- and 10-year data
MDedge Hematology and Oncology
CDC issues COVID-19 vaccine guidance for underlying conditions
MDedge Hematology and Oncology
2.1 Million COVID Vaccine Doses Given in U.S.
MDedge Hematology and Oncology
Patients with cancer a ‘high priority’ for COVID-19 vaccine, says AACR task force
MDedge Hematology and Oncology